Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?



Rating:

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Brussels, Belgium). Current place and future of immunotherapy in lung cancer. International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?

Member's Comments

No comment yet.

Related content which might interest you: New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 Boosting immunotherapy in lung cancer  Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer Year: 2017 Milestones in the management of lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Inhaled immunotherapy for lung cancer? Certainly possible. Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Innovative systemic lung cancer therapies Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016